Published in J Carcinog on March 05, 2014
Amplification of MUC1 in prostate cancer metastasis and CRPC development. Oncotarget (2016) 0.75
Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference. Prostate Int (2015) 0.75
Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines. Oncotarget (2016) 0.75
Upregulation of ULK1 expression in PC-3 cells following tumor protein P53 transfection by sonoporation. Oncol Lett (2015) 0.75
Upregulation of Beclin-1 expression in DU-145 cells following low-frequency ultrasound irradiation combined with microbubbles. Oncol Lett (2015) 0.75
Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line. Cancer Gene Ther (2016) 0.75
Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms. Front Pharmacol (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int (2008) 3.94
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin (1972) 3.35
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (2001) 3.06
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med (2000) 2.65
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol (1993) 1.86
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem (2004) 1.77
Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med (1984) 1.75
Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology (1994) 1.75
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73
Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res (2009) 1.72
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care (2008) 1.56
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res (2003) 1.55
Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet (1967) 1.46
Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr (1988) 1.38
Adrenal androgens and intracrinology. Semin Reprod Med (2004) 1.35
Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides (1999) 1.25
Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) (1985) 1.19
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology (2001) 1.18
Clinical development of anti-RANKL therapy. Arthritis Res Ther (2007) 1.17
Flare Associated with LHRH-Agonist Therapy. Rev Urol (2001) 1.16
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer (2007) 1.14
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev (2007) 1.08
LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs (2001) 1.07
Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology (2008) 1.07
Is the flare phenomenon clinically significant? Urology (2001) 1.03
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol (2002) 1.00
Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol (1974) 0.93
Withdrawal phenomenon with the antiandrogen casodex. J Urol (1995) 0.86
Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer (2010) 0.85
Antiandrogen withdrawal syndrome with nilutamide. J Urol (1997) 0.84
Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med (1997) 0.83
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci U S A (1984) 0.81
Hormonal therapy in prostate cancer: historical approaches. Rev Urol (2004) 0.80
Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer. Am J Ther (2009) 0.77